ADPT vs ILMN
ADPT: Adaptive Biotechnologies uses its proprietary immune medicine platform to decode the human immune system for cancer diagnostics and drug discovery. ILMN: Illumina provides the essential genetic sequencing and array platforms that power modern genomic research and clinical diagnostics.
Side-by-side fundamentals
| Metric | ADPT | ILMN | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $25.33 | $282.86 | |
| Market cap | $4.0B | $42.7B | |
| P/E as of 2026-10-21 | n/a | 52.77 | |
| Net margin FY2025, SEC XBRL | -21.5% | +19.6% | ILMN higher |
| Gross margin FY2025, SEC XBRL | n/a | +66.1% | |
| Operating margin FY2025, SEC XBRL | -20.6% | +18.6% | ILMN higher |
| ROE FY2025, SEC XBRL | -27.2% | +31.2% | ILMN higher |
| ROA FY2025, SEC XBRL | -11.6% | +12.8% | ILMN higher |
| Revenue growth (YoY) FY2025, SEC XBRL | +54.8% | -0.7% | ADPT higher |
| Revenue CAGR (3y) SEC XBRL | +14.3% | -1.4% | ADPT higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.62 | 1.02 | |
| 1-year return as of 2026-10-21 close | +46.0% | +185.8% | ILMN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.